Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database-Reference-Cited by-同舟云学术

Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database

Published:2021-01 Issue: Volume:3 Page:22-28
ISSN:2589-8450
Container-title:Surgery Open Science
language:en
Short-container-title:Surgery Open Science

Author:

Greco Stephanie H.,August David A.,Shah Mihir M.,Chen Chunxia,Moore Dirk F.,Masanam Monika,Turner Amber L.,Jabbour Salma K.,Javidian Parisa,Grandhi Miral S.,Kennedy Timothy J.,Alexander H. Richard,Carpizo Darren R.,Langan Russell C.

Publisher

Elsevier BV

Reference34 articles.

1. SEER Stat Fact Sheets: Pancreas cancer. Available: http://seer.cancer.gov/statfacts/html/pancreas.html [accessed December, 2017].

2. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer;Conroy;N Engl J Med,2018

3. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;Oettle;JAMA,2013

4. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer;Neoptolemos;N Engl J Med,2004

5. The importance of surgical margins in pancreatic cancer;Ethun;J Surg Oncol,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data;Langenbeck's Archives of Surgery;2024-08-22

2. Challenges during pancreatoduodenectomy and ways to overcome them;Siberian journal of oncology;2024-05-12

3. Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening;Pancreatic Cancer- Updates in Pathogenesis, Diagnosis and Therapies;2023-11-02

4. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A;JCO Oncology Practice;2023-03

5. Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis;JCO Oncology Practice;2023-03